Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted precision vascular systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures. Its CorPath system facilitates stent positioning for PCI procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision; and CorPath GRX system enables the precise robotic-assisted control of coronary guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CVRS
CUSIPN/A
Phone+1-508-6533335
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-323.84%
Return on Equity-110.93%
Return on Assets-88.11%
Miscellaneous
EmployeesN/A
Outstanding Shares188,790,000
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Frequently Asked Questions
What is Corindus Vascular Robotics' stock symbol?
Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."
How were Corindus Vascular Robotics' earnings last quarter?
Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) posted its quarterly earnings results on Tuesday, May, 8th. The medical equipment provider reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.03. The medical equipment provider had revenue of $1.49 million for the quarter, compared to analyst estimates of $3.20 million. Corindus Vascular Robotics had a negative return on equity of 110.93% and a negative net margin of 323.84%. View Corindus Vascular Robotics' Earnings History.
What price target have analysts set for CVRS?
2 brokerages have issued 12 month price targets for Corindus Vascular Robotics' stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Corindus Vascular Robotics' share price to reach $2.00 in the next year. View Analyst Ratings for Corindus Vascular Robotics.
Are investors shorting Corindus Vascular Robotics?
Corindus Vascular Robotics saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 14,032,950 shares, an increase of 7.7% from the May 15th total of 13,031,745 shares. Based on an average trading volume of 864,272 shares, the short-interest ratio is presently 16.2 days. Currently, 17.2% of the company's stock are sold short. View Corindus Vascular Robotics' Current Options Chain.
Who are some of Corindus Vascular Robotics' key competitors?
Some companies that are related to Corindus Vascular Robotics include Consort Medical (CSRT), Ekf Diagnostics (EKF), Bioquell (BQE), Immunodiagnostic Systems (IDH), Zecotek Photonics (ZMS), Theralase Technologies (TLT), LiDCO Group (LID), Medaphor Group (MED), InspireMD (NSPR), Lucid (LCDX), Verisante Technology (VRS) and Deltex Medical Group (DEMG).
Who are Corindus Vascular Robotics' key executives?
Corindus Vascular Robotics' management team includes the folowing people:
- Mr. Mark J. Toland, CEO, Pres & Director (Age 48)
- Mr. David W. Long, CFO, Sr. VP, Sec. & Treasurer (Age 48)
- Mr. Stephen Jeff Lemaster, Sr. VP & GM of Peripheral Intervention Segment (Age 47)
- Mr. Tal Wenderow, Co-Founder and Exec. VP of International & Bus. Devel.
- Mr. Doug Teany, Sr. VP of R&D and Operations
Has Corindus Vascular Robotics been receiving favorable news coverage?
Press coverage about CVRS stock has trended somewhat positive this week, according to Accern. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corindus Vascular Robotics earned a news impact score of 0.18 on Accern's scale. They also assigned media stories about the medical equipment provider an impact score of 45.62 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Corindus Vascular Robotics' major shareholders?
Corindus Vascular Robotics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.30%), Migdal Insurance & Financial Holdings Ltd. (0.11%), Bronfman E.L. Rothschild L.P. (0.06%) and The Manufacturers Life Insurance Company (0.05%). Company insiders that own Corindus Vascular Robotics stock include Healthcor Management, LP, Jeffrey Gold, Louis A Cannon and Philips Nv Koninklijke. View Institutional Ownership Trends for Corindus Vascular Robotics.
Which institutional investors are buying Corindus Vascular Robotics stock?
CVRS stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Migdal Insurance & Financial Holdings Ltd., Bronfman E.L. Rothschild L.P. and The Manufacturers Life Insurance Company . Company insiders that have bought Corindus Vascular Robotics stock in the last two years include Healthcor Management, LP, Jeffrey Gold and Louis A Cannon. View Insider Buying and Selling for Corindus Vascular Robotics.
How do I buy shares of Corindus Vascular Robotics?
Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corindus Vascular Robotics' stock price today?
One share of CVRS stock can currently be purchased for approximately $0.7104.
How big of a company is Corindus Vascular Robotics?
Corindus Vascular Robotics has a market capitalization of $272.68 million.
How can I contact Corindus Vascular Robotics?
Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.
MarketBeat Community Rating for Corindus Vascular Robotics (CVRS)
MarketBeat's community ratings are surveys of what our community members think about Corindus Vascular Robotics and other stocks. Vote "Outperform" if you believe CVRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
